Warfarin defends its position against direct oral anticoagulants in real world studies

Some recent real world studies have shown that anticoagulation treatment with direct oral anticoagulants (DOAC) contain issues not foreseen in clinical trials. Seems that especially poor adherence without close monitoring rises risks for DOAC users while warfarin patients with regular monitoring and high time in therapeutic range may stay safer. A German study published in 2018 with atrial fibrillation patients observed lower all-cause mortality, less hospitalization due to ischemic strokes and less severe bleedings with warfarin users compared to DOAC users.

Read more about the topic from our summary paper: Real world studies have revealed new information about Direct Oral Anticoagulants (DOACs)